

Reinhard BÄ¼ttner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1823895/publications.pdf>

Version: 2024-02-01

145
papers

9,579
citations

70961

41
h-index

42291

92
g-index

149
all docs

149
docs citations

149
times ranked

15000
citing authors

#	ARTICLE	IF	CITATIONS
1	Reference standards for gene fusion molecular assays on cytological samples: an international validation study. <i>Journal of Clinical Pathology</i> , 2023, 76, 47-52.	1.0	9
2	Precision medicine in non-small cell lung cancer: Current applications and future directions. <i>Seminars in Cancer Biology</i> , 2022, 84, 184-198.	4.3	106
3	Mutually Exclusive Expression of COL11A1 by CAFs and Tumour Cells in a Large panCancer and a Salivary Gland Carcinoma Cohort. <i>Head and Neck Pathology</i> , 2022, 16, 394-406.	1.3	7
4	Adenoma and colorectal cancer risks in Lynch syndrome, Lynch-like syndrome and familial colorectal cancer type X. <i>International Journal of Cancer</i> , 2022, 150, 56-66.	2.3	2
5	Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 76-88.	0.5	37
6	TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: an international performance evaluation study. <i>Journal of Clinical Pathology</i> , 2022, 75, 416-421.	1.0	6
7	The E3 ligase COP1 promotes ER α signaling and suppresses EMT in breast cancer. <i>Oncogene</i> , 2022, 41, 173-190.	2.6	8
8	Invasive mucinous adenocarcinoma: genetic insights into a lung cancer entity with distinct clinical behavior and genomic features. <i>Modern Pathology</i> , 2022, 35, 138-139.	2.9	3
9	Prevalence of abnormal Pap smear results in inflammatory bowel disease: a prospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 3071-3079.	1.2	3
10	Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe. <i>Journal of Personalized Medicine</i> , 2022, 12, 72.	1.1	26
11	Transcriptome analysis reveals upregulation of immune response pathways at the invasive tumour front of metastatic seminoma germ cell tumours. <i>British Journal of Cancer</i> , 2022, 126, 937-947.	2.9	8
12	Diffusion kernel-based predictive modeling of KRAS dependency in KRAS wild type cancer cell lines. <i>Npj Systems Biology and Applications</i> , 2022, 8, 2.	1.4	0
13	Autophagy-Related Activation of Hepatic Stellate Cells Reduces Cellular miR-29a by Promoting Its Vesicular Secretion. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 1701-1716.	2.3	12
14	Molecular Diagnostics of Lung Cancer in Serous Effusion Samples. <i>Journal of Molecular Pathology</i> , 2022, 3, 78-87.	0.5	2
15	Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications. <i>Lung Cancer</i> , 2022, 168, 10-20.	0.9	6
16	CD74-NRG1 Fusions Are Oncogenic <i>In Vivo</i> and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 821-830.	1.9	4
17	The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia. <i>Leukemia</i> , 2022, 36, 1794-1805.	3.3	1
18	Crizotinib in ROS1-rearranged lung cancer (EUCROSS): Updated overall survival.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9078-9078.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Metastatic patterns plus clinical and molecular characteristics of <i>ROS1</i> aberrations in non-small cell lung cancer patients without rearrangements.. Journal of Clinical Oncology, 2022, 40, e21117-e21117.	0.8	0
20	Microsatellite instability and sex differences in resectable gastric cancer – A pooled analysis of three European cohorts. European Journal of Cancer, 2022, 173, 95-104.	1.3	9
21	Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung Cancer, 2021, 152, 174-184.	0.9	53
22	Tumor budding assessed according to the criteria of the International Tumor Budding Consensus Conference determines prognosis in resected esophageal adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 393-400.	1.4	13
23	Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence. Lung Cancer, 2021, 151, 91-96.	0.9	5
24	Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. Genetics in Medicine, 2021, 23, 705-712.	1.1	28
25	Deep Learning Predicts HPV Association in Oropharyngeal Squamous Cell Carcinomas and Identifies Patients with a Favorable Prognosis Using Regular H&E Stains. Clinical Cancer Research, 2021, 27, 1131-1138.	3.2	32
26	GATA binding protein 6 (GATA6) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1031-1040.	1.2	5
27	Value of upper gastrointestinal endoscopy for gastric cancer surveillance in patients with Lynch syndrome. International Journal of Cancer, 2021, 148, 106-114.	2.3	28
28	Data driven precision medicine: who is the driver?. Oncotarget, 2021, 12, 253-254.	0.8	1
29	Awakening of SCHLAFEN 11 by immunohistochemistry: a new biomarker predicting response to chemotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 567-568.	1.4	3
30	Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation. BMC Medical Genomics, 2021, 14, 62.	0.7	58
31	Protein loss of SWI/SNF complex core subunits influences prognosis dependent on histological subtypes of intra- and extrahepatic cholangiocarcinoma. Oncology Letters, 2021, 21, 349.	0.8	6
32	The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. Lung Cancer, 2021, 154, 161-175.	0.9	105
33	Notch1 Deficiency Induces Tumor Cell Accumulation Inside the Bronchiolar Lumen and Increases TAZ Expression in an Autochthonous KrasLSL-G12V Driven Lung Cancer Mouse Model. Pathology and Oncology Research, 2021, 27, 596522.	0.9	1
34	Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. European Journal of Cancer, 2021, 148, 124-133.	1.3	11
35	Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nature Communications, 2021, 12, 2540.	5.8	295
36	Pericentromeric Satellite III transcripts induce etoposide resistance. Cell Death and Disease, 2021, 12, 530.	2.7	9

#	ARTICLE	IF	CITATIONS
37	No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2856.	1.0	11
38	Quality control stress test for deep learning-based diagnostic model in digital pathology. <i>Modern Pathology</i> , 2021, 34, 2098-2108.	2.9	72
39	Early detection of duodenal cancer by upper gastrointestinal endoscopy in Lynch syndrome. <i>International Journal of Cancer</i> , 2021, 149, 2052-2062.	2.3	4
40	Cardiac metastasis causes paradoxical malignant embolism. <i>Cancer Reports</i> , 2021, , e1513.	0.6	2
41	Quantum Cascade Laser-Based Infrared Imaging as a Label-Free and Automated Approach to Determine Mutations in Lung Adenocarcinoma. <i>American Journal of Pathology</i> , 2021, 191, 1269-1280.	1.9	7
42	Genomic and Transcriptomic Characteristics of Esophageal Adenocarcinoma. <i>Cancers</i> , 2021, 13, 4300.	1.7	4
43	Shifting Gears in Precision Oncology—Challenges and Opportunities of Integrative Data Analysis. <i>Biomolecules</i> , 2021, 11, 1310.	1.8	3
44	MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. <i>Nature Communications</i> , 2021, 12, 5505.	5.8	30
45	Sarcoma classification by DNA methylation profiling. <i>Nature Communications</i> , 2021, 12, 498.	5.8	237
46	High sensitivity of PD-L1 analysis from pleural effusion in nonsmall cell lung cancer. <i>ERJ Open Research</i> , 2021, 7, 00787-2020.	1.1	2
47	LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma—Potential Biomarkers for Targeted Therapy Concepts. <i>International Journal of Molecular Sciences</i> , 2021, 22, 379.	1.8	24
48	A Novel Autochthonous Mouse Model Serves As a Preclinical Evaluation Platform and Explores Dual BTK and BCL2 Inhibition for Activated B Cell-like Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2021, 138, 712-712.	0.6	1
49	Mismatch Repair Deficiency and Somatic Mutations in Human Sinonasal Tumors. <i>Cancers</i> , 2021, 13, 6081.	1.7	9
50	Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer. <i>Npj Precision Oncology</i> , 2021, 5, 102.	2.3	11
51	Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. <i>Genetics in Medicine</i> , 2020, 22, 15-25.	1.1	365
52	ATM activity in T cells is critical for immune surveillance of lymphoma in vivo. <i>Leukemia</i> , 2020, 34, 771-786.	3.3	13
53	Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma. <i>BMC Cancer</i> , 2020, 20, 12.	1.1	35
54	PIK3CA and KRAS Amplification in Esophageal Adenocarcinoma and their Impact on the Inflammatory Tumor Microenvironment and Prognosis. <i>Translational Oncology</i> , 2020, 13, 157-164.	1.7	29

#	ARTICLE	IF	CITATIONS
55	Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing. <i>Scientific Reports</i> , 2020, 10, 11387.	1.6	33
56	PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5228.	1.8	19
57	Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1300-1307.	1.2	9
58	Integrin alpha V (ITGAV) expression in esophageal adenocarcinoma is associated with shortened overall-survival. <i>Scientific Reports</i> , 2020, 10, 18411.	1.6	22
59	Expression Profiling of Extracellular Matrix Genes Reveals Global and Entity-Specific Characteristics in Adenoid Cystic, Mucoepidermoid and Salivary Duct Carcinomas. <i>Cancers</i> , 2020, 12, 2466.	1.7	19
60	Combining biopsy tools improves mutation detection rate in central lung cancer. <i>ERJ Open Research</i> , 2020, 6, 00002-2020.	1.1	0
61	Integrative Analysis of Pleomorphic Dermal Sarcomas Reveals Fibroblastic Differentiation and Susceptibility to Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 5638-5645.	3.2	21
62	Deep learning for sensitive detection of Helicobacter Pylori in gastric biopsies. <i>BMC Gastroenterology</i> , 2020, 20, 417.	0.8	23
63	Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. <i>Biomedicine Hub</i> , 2020, 5, 1-42.	0.4	15
64	Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations. <i>Lung Cancer</i> , 2020, 144, 40-48.	0.9	9
65	Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. <i>Cancer Medicine</i> , 2020, 9, 4991-5007.	1.3	14
66	Mesothelin expression in esophageal adenocarcinoma and squamous cell carcinoma and its possible impact on future treatment strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091757.	1.4	10
67	The X-linked trichothiodystrophy-causing gene RNF113A links the spliceosome to cell survival upon DNA damage. <i>Nature Communications</i> , 2020, 11, 1270.	5.8	26
68	Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1363-1373.	2.0	26
69	Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2319-2327.	1.2	25
70	Dickkopf-2 (DKK2) as Context Dependent Factor in Patients with Esophageal Adenocarcinoma. <i>Cancers</i> , 2020, 12, 451.	1.7	7
71	Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome. <i>Gastroenterology</i> , 2020, 158, 1326-1333.	0.6	60
72	Cell type-specific transcriptomics of esophageal adenocarcinoma as a scalable alternative for single cell transcriptomics. <i>Molecular Oncology</i> , 2020, 14, 1170-1184.	2.1	8

#	ARTICLE	IF	CITATIONS
73	Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study. <i>BMC Cancer</i> , 2020, 20, 460.	1.1	32
74	Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies. <i>Oncology Letters</i> , 2020, 19, 3665-3670.	0.8	13
75	The Scaffolding Protein NEDD9 Regulates Chronic Lymphocytic Leukemia Cell Migration Via the CXCR4 - CXCL12 Axis and Promotes Disease Progression. <i>Blood</i> , 2020, 136, 2-2.	0.6	0
76	First report on two cases of pleomorphic dermal sarcoma successfully treated with immune checkpoint inhibitors. <i>Oncolimmunology</i> , 2019, 8, e1665977.	2.1	21
77	Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumors. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 1339-1347.	1.9	16
78	Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma. <i>BMC Gastroenterology</i> , 2019, 19, 21.	0.8	6
79	Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. <i>Cancer Cytopathology</i> , 2019, 127, 285-296.	1.4	39
80	The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma. <i>Oncolimmunology</i> , 2019, 8, e1581546.	2.1	59
81	Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 973-982.	2.0	21
82	Bronchoscopic Brushing from Central Lung Cancer – Next Generation Sequencing Results are Reliable. <i>Lung</i> , 2019, 197, 333-337.	1.4	7
83	Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	1.5	17
84	K-ras Mutation Subtypes in NSCLC and Associated Co-occurring Mutations in Other Oncogenic Pathways. <i>Journal of Thoracic Oncology</i> , 2019, 14, 606-616.	0.5	178
85	Genomic Characterization of TP53 – Wild-Type Esophageal Carcinoma. <i>Translational Oncology</i> , 2019, 12, 154-161.	1.7	8
86	BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – Preliminary results from the SCLC cohort.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8563-8563.	0.8	4
87	Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial – Updated report on progression-free and overall survival.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9066-9066.	0.8	2
88	BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – Preliminary results from the NSCLC cohort.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20550-e20550.	0.8	3
89	Overcoming acquired osimertinib-resistance in EGFR-mutant advanced non-small lung cancer mediated by activating BRAF V600E mutation.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20682-e20682.	0.8	2
90	Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. <i>Nature Communications</i> , 2018, 9, 727.	5.8	160

#	ARTICLE	IF	CITATIONS
91	LIN28B enhanced tumorigenesis in an autochthonous KRASG12V-driven lung carcinoma mouse model. <i>Oncogene</i> , 2018, 37, 2746-2756.	2.6	16
92	The landscape of genetic alterations in ameloblastomas relates to clinical features. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 807-814.	1.4	46
93	Does volumetric measurement serve as an imaging biomarker for tumor aggressiveness of ameloblastomas?. <i>Oral Oncology</i> , 2018, 78, 16-24.	0.8	5
94	AATF suppresses apoptosis, promotes proliferation and is critical for Kras-driven lung cancer. <i>Oncogene</i> , 2018, 37, 1503-1518.	2.6	26
95	Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.	1.5	2
96	Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. <i>Nature Communications</i> , 2018, 9, 4655.	5.8	107
97	A mechanistic classification of clinical phenotypes in neuroblastoma. <i>Science</i> , 2018, 362, 1165-1170.	6.0	213
98	No Difference in Colorectal Cancer Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch Syndrome Surveillance Policies. <i>Gastroenterology</i> , 2018, 155, 1400-1409.e2.	0.6	112
99	Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer. <i>Cancer Research</i> , 2018, 78, 4270-4281.	0.4	117
100	Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. <i>Oncogene</i> , 2018, 37, 5682-5693.	2.6	29
101	Copy number variation analysis and targeted NGS in 77 families with suspected Lynch syndrome reveals novel potential causative genes. <i>International Journal of Cancer</i> , 2018, 143, 2800-2813.	2.3	11
102	Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance. <i>Genome Medicine</i> , 2018, 10, 55.	3.6	37
103	Comparative proteomics reveals a diagnostic signature for pulmonary head&neck cancer&metastasis. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	41
104	Genetic instability and recurrent <i>MYC</i> amplification in <i>ALK</i> -translocated NSCLC: a central role of <i>TP53</i> mutations. <i>Journal of Pathology</i> , 2018, 246, 67-76.	2.1	52
105	Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events. <i>Human Pathology</i> , 2017, 62, 206-214.	1.1	50
106	Mechanisms of Primary Drug Resistance in <i>FGFR1</i> -Amplified Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5527-5536.	3.2	44
107	Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target. <i>Molecular and Clinical Oncology</i> , 2017, 6, 639-642.	0.4	11
108	Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	55

#	ARTICLE	IF	CITATIONS
109	Molecular Profiling of Odontogenic Tumors - Pilot Study. <i>Balkan Journal of Dental Medicine</i> , 2017, 21, 112-115.	0.2	2
110	Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. <i>Cell Reports</i> , 2017, 20, 2833-2845.	2.9	40
111	Somatic BRCA1-associated protein 1 (BAP1) loss is an early and rare event in esophageal adenocarcinoma. <i>Molecular and Clinical Oncology</i> , 2017, 7, 225-228.	0.4	7
112	Exome sequencing characterizes the somatic mutation spectrum of early serrated lesions in a patient with serrated polyposis syndrome (SPS). <i>Hereditary Cancer in Clinical Practice</i> , 2017, 15, 22.	0.6	6
113	Notch signaling triggers the tumor heterogeneity of small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 4884-4888.	0.6	7
114	High protein and mRNA expression levels of TUBB3 (class III β -tubulin) are associated with aggressive tumor features in esophageal adenocarcinomas. <i>Oncotarget</i> , 2017, 8, 115179-115189.	0.8	13
115	Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. <i>Modern Pathology</i> , 2016, 29, 1165-1172.	2.9	340
116	B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice. <i>Blood</i> , 2016, 127, 2732-2741.	0.6	99
117	STAT3/IRF1 Pathway Activation Sensitizes Cervical Cancer Cells to Chemotherapeutic Drugs. <i>Cancer Research</i> , 2016, 76, 3872-3883.	0.4	43
118	Exome Sequencing Identifies Biallelic MSH3 Germline Mutations as a Recessive Subtype of Colorectal Adenomatous Polyposis. <i>American Journal of Human Genetics</i> , 2016, 99, 337-351.	2.6	198
119	<scp>NOTCH</scp>, <scp>ASCL1</scp>, p53 and <scp>RB</scp> alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. <i>International Journal of Cancer</i> , 2016, 138, 927-938.	2.3	143
120	Unusual Presentation of an Adenocarcinoma of the Lung Metastasizing to the Mandible, Including Molecular Analysis and a Review of the Literature. <i>Journal of Oral and Maxillofacial Surgery</i> , 2016, 74, 2007.e1-2007.e8.	0.5	8
121	Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. <i>Clinical Cancer Research</i> , 2016, 22, 4837-4847.	3.2	223
122	Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. <i>Gut</i> , 2016, 65, 1296-1305.	6.1	65
123	Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. <i>Oncotimmunology</i> , 2016, 5, e1100789.	2.1	45
124	NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 697-705.	1.4	24
125	Loss of the LIM-only protein Fhl2 impairs inflammatory reaction and scar formation after cardiac ischemia leading to better hemodynamic performance. <i>Life Sciences</i> , 2016, 151, 348-358.	2.0	8
126	Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients. <i>Journal of Thoracic Oncology</i> , 2016, 11, 122-127.	0.5	65

#	ARTICLE	IF	CITATIONS
127	miRNAâ€221 and miRNAâ€222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours. <i>Molecular Oncology</i> , 2015, 9, 1421-1433.	2.1	71
128	Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1049-1057.	0.5	85
129	Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases. <i>Experimental and Molecular Pathology</i> , 2015, 99, 682-686.	0.9	12
130	Comprehensive genomic profiles of small cell lung cancer. <i>Nature</i> , 2015, 524, 47-53.	13.7	1,634
131	Rationale, design and objectives of ARegPKD, a European ARPKD registry study. <i>BMC Nephrology</i> , 2015, 16, 22.	0.8	46
132	Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy. <i>BMC Cancer</i> , 2015, 15, 291.	1.1	7
133	<i>MET</i> Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung. <i>Clinical Cancer Research</i> , 2015, 21, 907-915.	3.2	155
134	Telomerase activation by genomic rearrangements in high-risk neuroblastoma. <i>Nature</i> , 2015, 526, 700-704.	13.7	478
135	Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation Sequencing. <i>PLoS ONE</i> , 2015, 10, e0129544.	1.1	23
136	<i>ROS1</i> rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. <i>Oncotarget</i> , 2015, 6, 10577-10585.	0.8	85
137	The LIM-Only Protein FHL2 Reduces Vascular Lesion Formation Involving Inhibition of Proliferation and Migration of Smooth Muscle Cells. <i>PLoS ONE</i> , 2014, 9, e94931.	1.1	17
138	Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. <i>Nature Communications</i> , 2014, 5, 3518.	5.8	239
139	<i>CD74</i> â€“ <i>NRG1</i> Fusions in Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2014, 4, 415-422.	7.7	238
140	Changing Histopathological Diagnostics by Genome-Based Tumor Classification. <i>Genes</i> , 2014, 5, 444-459.	1.0	12
141	Comparison of TNM-based stage grouping versus UICC/AJCC stage grouping (7th edition) in malignant parotid gland tumors. <i>Oral Oncology</i> , 2013, 49, 903-910.	0.8	14
142	Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas. <i>Genome Biology</i> , 2013, 14, r137.	13.9	78
143	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. <i>Nature Genetics</i> , 2012, 44, 1104-1110.	9.4	1,186
144	Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast. <i>BMC Clinical Pathology</i> , 2012, 12, 13.	1.8	63

#	ARTICLE	IF	CITATIONS
145	Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. International Journal of Cancer, 2012, 131, 2704-2709.	2.3	118